1. Pink Sheet
  2. >>Geography

EU’s Plans for Regulatory Data Protection ‘Unworkable’

 
• By Ian Schofield

The European Commission will have a fight on its hands when it comes to the data protection part of its proposals for EU pharma legislative reform.

European Flags in front of the European Commission Headquarters building in Brussels, Belgium
The European Commission has proposed a raft of revisions to the pharmaceutical legislation • Source: Shutterstock

A real challenge, almost impossible, unworkable. Just a few of the comments made by life science lawyers keeping a close eye on the European Commission’s proposals for new rules on regulatory data protection (RDP) periods.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

US FDA Asks Adcomm If Opioid Postmarketing Studies Are Relevant, Warrant Action

 
• By Sue Sutter

Two US FDA advisory committees will discuss results from epidemiological studies that attempted to quantify the prevalence, incidence and risk factors for misuse, abuse, overdose and death with opioid analgesics.

Raising Drug Prices In The EU Could Take Years, Even If Pharma Effort Succeeds

 
• By Cathy Kelly

Manufacturers are engaging the European Commission and individual countries to allocate more health care spending to innovative medicines and align prices more closely to those in the US.

Non-Submissions To UK HTA Body Could Increase Unless Commercial Environment Improves, Warns Industry

 
• By Leela Barham

Finding ways to lower the rebates paid by the pharmaceutical industry to the UK government and fostering partnerships to make the UK a more attractive launch market could help reduce the number of terminated technology appraisals conducted by NICE, the health technology appraisal institute, says the UK pharmaceutical industry.